AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24495641
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of a mixture of 65% nitrous oxide and oxygen during dressing change
Trial: 24495641
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of oxygen during dressing change
Trial: 21626011
Drug: Lidocaine concentration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine concentration of 8 mg/mL
Trial: 21626011
Drug: Lidocaine concentration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine concentration of 5 mg/mL
Trial: 21626011
Drug: Lidocaine concentration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine concentration of 3.3 mg/mL
Trial: 16515571
Drug: Epidoxorubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidoxorubicin 120 mg/sqm for 4 months
Trial: 8021765
Drug: Zidovudine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (60 to 180 mg/m2 per dose) given orally every 6 hours
Trial: 8021765
Drug: Didanosine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine (60 to 180 mg/m2 per dose) given every 12 hours
Trial: 8021765
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of zidovudine and didanosine
Trial: 8021765
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and didanosine after 4 and 12 weeks of treatment
Trial: 810269
Drug: 2% solution
RxNorm normalized name: Lidomar 2% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% solution of sodium cromoglycate (SCG), administered as a fine spray six times a day for 4 weeks, approximately 31-32 mg daily.
Trial: 810269
Drug: Placebo solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution, administered as a fine spray six times a day for 4 weeks.
Trial: 29232379
Drug: sufentanil 0.1
RxNorm normalized name: bupivacaine-sufentanil 0.1%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 0.1 μg/kg (group S)
Trial: 29232379
Drug: nalbuphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.1 mg/kg (group N1)
Trial: 29232379
Drug: nalbuphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.15 mg/kg (group N2)
Trial: 29232379
Drug: nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.2 mg/kg (group N3)
Trial: 26225794
Drug: 5α-reductase inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5α-reductase inhibitors (5αRIs) for 3 years after TURP
Trial: 23072267
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus aromatherapy (rose essential oil)
Trial: 23072267
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus placebo (physiological serum, 0.9% NaCl)
Trial: 19801025
Drug: Bolus plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus plus bivalirudin infusion during and after PCI (4 hours, n = 88)
Trial: 19801025
Drug: Bolus plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus plus bivalirudin infusion during PCI (n = 90)
Trial: 16788335
Drug: Early access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early access to physical therapy treatment within 2 days (n=32)
Trial: 1691882
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg i.v.)
Trial: 26923352
Drug: Steroid-sparing immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sparing immunosuppressive regimens
Trial: 26923352
Drug: JCPyV positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JCPyV positive donor IgG antibodies
Trial: 21414035
Drug: 3% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months
Trial: 21414035
Drug: 3% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 6 months
Trial: 21414035
Drug: 3% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac in 2.5% hyaluronic acid gel for 3 months and 6 months
Trial: 15105027
Drug: High-protein liquid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein liquid nutritional supplement (Boost HP)
Trial: 15105027
Drug: Standard liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard liquid nutritional supplement (Ensure)
Trial: 9589230
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g daily for 2 months)
Trial: 9589230
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (6 g daily for 2 months)
Trial: 2660451
Drug: UDCG 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCG 115 BS (5 mg)
Trial: 2660451
Drug: UDCG 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCG 115 BS (10 mg)
Trial: 2660451
Drug: UDCG 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCG 115 BS (chronic treatment: 2 x 5 or 2 x 10 mg/d)
Trial: 30329038
Drug: Maribavir 800
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 800 mg twice daily
Trial: 30329038
Drug: Maribavir 1200
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 1200 mg twice daily
Trial: 30329038
Drug: Maribavir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maribavir (all doses combined)
Trial: 28474460
Drug: OXN PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN PR (oxycodone-naloxone prolonged-release) at a mean daily dose of 130.7 mg (range 120-180 mg)
Trial: 28474460
Drug: OXN PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN PR (oxycodone-naloxone prolonged-release)
Trial: 21231888
Drug: Amitriptyline buccoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline buccoadhesive tablets
Trial: 21231888
Drug: Amitriptyline buccoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline buccoadhesive tablets with high-viscosity hydroxypropylmethyl cellulose (HPMC-K4M)
Trial: 21231888
Drug: Amitriptyline buccoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline buccoadhesive tablets with sodium carboxymethyl cellulose (NaCMC) and HPMC-E5LV
Trial: 21231888
Drug: Amitriptyline buccoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline buccoadhesive tablets with HPMC-E5LV
Trial: 19728577
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment (fixed appliance treatment)
Trial: 10933062
Drug: Tirapazamine (TPZ)
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirapazamine (TPZ) administration
Trial: 8569225
Drug: Ketanserin between
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin between 8 and 12 weeks of rHuEpo therapy
Trial: 8569225
Drug: Ketanserin administration
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin administration
Trial: 2037667
Drug: Intranasal bivalent
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal bivalent live attenuated influenza vaccine
Trial: 2037667
Drug: Parenteral trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral trivalent inactivated subvirion vaccine
Trial: 6909025
Drug: Timolol 5
RxNorm normalized name: timolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 5 mg/day + 1% adrenaline eye drops
Trial: 6909025
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg/day + 1% adrenaline eye drops
Trial: 6909025
Drug: Timolol 5
RxNorm normalized name: timolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 5 mg/day + placebo eye drops
Trial: 6909025
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg/day + placebo eye drops
Trial: 29463288
Drug: Dihydroartemisinin-piperaquine treatment
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine treatment administered through the local health system.
Trial: 18083404
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with fluorouracil and folinic acid (n=1622)
Trial: 16139122
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose before PCI and 75 mg daily for one year afterward
Trial: 10456461
Drug: PAP levels
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP levels in patients receiving warfarin
Trial: 21757914
Drug: Rebamipide 300
RxNorm normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide 300 mg daily for 7 weeks
Trial: 21757914
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 7 weeks
Trial: 15139576
Drug: Adjustable dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Trial: 15139576
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Trial: 10796741
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate, bolus 30mg/kg over 15 minutes with a maintenance infusion of 5.4 mg/kg per hour for 23 hours.
Trial: 10796741
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate, extended maintenance dose from 24 to 48 hours.
Trial: 10796741
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate, therapy for whiplash injuries.
Trial: 1751444
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet (20 mmol sodium daily)
Trial: 8312208
Drug: Azithromycin (1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1g single dose)
Trial: 30545921
Drug: Cyclophosphamide (440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (440 mg/m2 days 1-5) / Etoposide (100 mg/m2 days 1-5) during part 2 of consolidation and delayed intensification
Trial: 26218256
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (target blood glucose, 4-7 mmol/L) with insulin titration based on blood glucose values and rate of change.
Trial: 18469350
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (5.2 g daily for 12 weeks)
Trial: 16517955
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral 800 IU vitamin E and 500 mg vitamin C (n = 24)
Trial: 16517955
Drug: B-group vitamins
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-group vitamins (5 mg folic acid, 5 mg vitamin B(2), 50 mg vitamin B(6), and 0.4 mg of vitamin B(12); n = 24)
Trial: 10921768
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg once daily) with salmeterol placebo
Trial: 10921768
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (100 microg daily) with montelukast placebo
Trial: 8725733
Drug: Aspirin (330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (330 mg/day)
Trial: 8725733
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiplatelet medication)
Trial: 1533312
Drug: Pulsed intra-nasal
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed intra-nasal mupirocin ointment
Trial: 3890132
Drug: L-carnitine, 2
RxNorm normalized name: L-Carnitine, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine, 2 g i.v. three times per week
Trial: 29328027
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (recombinant growth hormone injection once weekly for 12 months)
Trial: 23207959
Drug: Imidafenacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin (0.1 mg twice daily)
Trial: 30637134
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin therapy
Trial: 22041946
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (aspirin alone)
Trial: 17625501
Drug: Dapoxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 30 mg orally twice daily
Trial: 17135729
Drug: Intravenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GLP-1 (0.9 pmol/kg/min)
Trial: 17135729
Drug: Intravenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GLP-1 (0.9 pmol/kg/min) with a protein preload (400 ml protein shake)
Trial: 17135729
Drug: Preload of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preload of 400 ml water or 400 ml protein shake
Trial: 11152378
Drug: Guanabenz (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz (oral administration for 2 weeks)
Trial: 9461727
Drug: Allergovit immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergovit immunotherapy
Trial: 7530963
Drug: Tricyclic drugs
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic drugs
Trial: 20696154
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg GMZ2 vaccine
Trial: 18240099
Drug: Echinaforce tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinaforce tablets
Trial: 18240099
Drug: Echinaforce Junior
RxNorm normalized name: Disprol Junior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinaforce Junior tablets
Trial: 18240099
Drug: Echinacea sore
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea sore throat spray
Trial: 16548353
Drug: Raw rhubarb
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw rhubarb (RR) 9 g/d
Trial: 12834313
Drug: Immunoglobulin at
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin at doses of 50 mg/kg, 250 mg/kg, or 500 mg/kg weekly from day ‐7 to day 100 after transplantation
Trial: 11728260
Drug: Lisinopril with
RxNorm normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril with ASA
Trial: 11728260
Drug: Lisinopril without
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril without ASA
Trial: 11728260
Drug: ASA and
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA and Lisinopril
Trial: 1531677
Drug: Albuterol and
RxNorm normalized name: Albuterol and cromolyn only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol and ipratropium bromide
Trial: 6374684
Drug: Proxyphylline (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxyphylline (2400 mg/day)
Trial: 6374684
Drug: Theophylline (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (800 mg/day)
Trial: 31278225
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus of IV ondansetron at a dose of 0.2 mg/kg
Trial: 27291501
Drug: Testosterone solution
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone solution 2% (TS)
Trial: 20522464
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg for 5-12 years, 10 mg for >12 years)
Trial: 18525261
Drug: 6-week antiretroviral
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week antiretroviral therapy interruption
Trial: 18525261
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy interruption extended to viral set point
Trial: 18525261
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of antiretroviral therapy
Trial: 15996071
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg IL-1Ra
Trial: 9569804
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy with local metronidazole administration
Trial: 9569804
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy without local metronidazole administration
Trial: 29196963
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene (TOR) 40 mg/day
Trial: 29196963
Drug: Letrozole (LET)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (LET) 2.5 mg/day
Trial: 26948184
Drug: 200-mg mifepristone
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg mifepristone followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Trial: 26948184
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Trial: 21749167
Drug: Experimental Treatment
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Treatment Group (ETG): plaque control and root planing plus amoxicillin and metronidazole
Trial: 21749167
Drug: Control Treatment
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control Treatment Group (CTG): plaque control instructions, supragingival scaling, and two placebos
Trial: 21749167
Drug: Experimental Treatment
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Treatment Group (ETG)
Trial: 20729710
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream applied three times a week for 4 months
Trial: 20729710
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied three times a week for 4 months
Trial: 20729710
Drug: Open-label imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label imiquimod treatment for a further 4 months after initial treatment
Trial: 20729710
Drug: Overall follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall follow-up after treatment
Trial: 9814491
Drug: Isoproterenol (10(-6)
RxNorm normalized name: isoproterenol sulfate 0.6 MG/ML
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol (10(-6) mol/L)
Trial: 8123955
Drug: Telephone contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone contact intervention (weekly calls from a healthcare professional during the first month of drug therapy)
Trial: 2510286
Drug: Rioprostil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil + Aspirin